Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab (CNTO 1275) Phase 2 in Moderate to Severe Psoriasis
NCT00320216Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2003
- Primary completion
- Jun 2004
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ustekinumab in plaque psoriasis, sponsored by Janssen Pharmaceutical. Started Nov 2003; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00320216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00320216.